{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:42:25Z","timestamp":1792593745586,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T00:00:00Z","timestamp":1633219200000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.revmed.2020.07.002","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T07:57:14Z","timestamp":1597737434000},"page":"673-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["L'amylose cardiaque \u00e0 transthyr\u00e9tine"],"prefix":"10.1016","volume":"41","author":[{"given":"J.C.","family":"Eicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Audia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.07.002_bb0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/eurheartj\/ehy697","article-title":"Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?","volume":"40","author":"Falk","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2020.07.002_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.revmed.2020.07.002_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352","article-title":"Afro-Caribbean heart failure in the United Kingdom: cause, outcomes, and ATTR V122I cardiac amyloidosis","volume":"9","author":"Dungu","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0030","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0045","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65\u00a0years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jchf.2017.04.006","article-title":"Cardiac amyloidosis as a potential confounder in heart failure with preserved ejection fraction trials","volume":"5","author":"Schelbert","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jacc.2014.09.084","article-title":"Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac amyloidosis?","volume":"65","author":"Castano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0065","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","article-title":"Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?","volume":"37","author":"Galat","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.carpath.2009.04.005","article-title":"High prevalence of amyloid in 150 surgically removed heart valves-a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions","volume":"19","author":"Kristen","year":"2010","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.revmed.2020.07.002_bb0080","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0085","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","article-title":"Aortic stenosis and cardiac amyloidosis: JACC review topic of the week","volume":"74","author":"Ternacle","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin amyloidosis cardiac study (TRACS)","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0095","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0100","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/13506129.2019.1663814","article-title":"Association between hearing loss and hereditary ATTR amyloidosis","volume":"26","author":"Bartier","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0105","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0110","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.revmed.2020.07.002_bb0115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1161\/CIRCIMAGING.113.000683","article-title":"Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy","volume":"6","author":"Liu","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","article-title":"Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis","volume":"9","author":"Ternacle","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s00380-016-0925-8","article-title":"Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy","volume":"32","author":"Yamamura","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.revmed.2020.07.002_bb0130","first-page":"1128","article-title":"Left atrial structure and function in cardiac amyloidosis","volume":"18","author":"Nochioka","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/13506129.2016.1194264","article-title":"Prognostic value of right ventricular systolic function in cardiac amyloidosis","volume":"23","author":"Bodez","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","article-title":"Right ventricular involvement in transthyretin amyloidosis","volume":"25","author":"Arvidsson","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0145","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2020.07.002_bb0150","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/hrt.75.4.426-b","article-title":"Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation","volume":"75","author":"Stables","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.revmed.2020.07.002_bb0155","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardised methods of imaging","volume":"25","author":"Dorbala","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0170","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/13506129.2015.1072089","article-title":"Usefulness of (99\u00a0m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis","volume":"22","author":"Galat","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcmg.2016.05.007","article-title":"Early phase (99)Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis","volume":"10","author":"Galat","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0185","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jcmg.2016.07.008","article-title":"Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation","volume":"9","author":"Algalarrondo","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.revmed.2020.07.002_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","article-title":"Outcomes in patients with cardiac amyloidosis undergoing heart transplantation","volume":"8","author":"Barrett","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.revmed.2020.07.002_bb0200","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy","volume":"47","author":"Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2020.07.002_bb0205","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.revmed.2020.07.002_bb0215","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2020.07.002_bb0220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0225","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.2147\/DDDT.S96893","article-title":"Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study","volume":"9","author":"Aus dem Siepen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.revmed.2020.07.002_bb0230","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.07.002_bb0235","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.revmed.2020.07.002_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Castano","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.revmed.2020.07.002_bb0245","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.07.002_bb0250","article-title":"The tafamidis in transthyretin cardiomyopathy clinical trial","author":"Damy","year":"2020","journal-title":"Heart Fail Congr"},{"key":"10.1016\/j.revmed.2020.07.002_bb0255","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.07.002_bb0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.revmed.2020.07.002_bb0265","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.revmed.2020.07.002_bb0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.07.002_bb0275","first-page":"219","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320302496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:10:19Z","timestamp":1792591819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320302496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0248866320302496"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.07.002","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L'amylose cardiaque \u00e0 transthyr\u00e9tine","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI).","name":"copyright","label":"Copyright"}]}}